Oxolife

Oxolife is a professional biotechnology company that focuses on enhancing embryo implantation in women undergoing assisted reproductive technology (ART) fertility treatments. Its lead compound, OXO-001, is an easy-to-take non-hormonal oral pill that promotes endometrial adhesion and embryo invasion, which are key factors in improving pregnancy success rates. OXO-001 has completed Phase II studies. Oxolife is currently raising funds through clinics to accelerate the progress of OXO-001 and is exploring potential partnerships to bring OXO-001 to patients as soon as possible.